

Novo Nordisk Invest 4 A/S

c/o Novo Nordisk A/S
Novo Allé
2880 Bagsværd
Denmark

CVR number 31 85 39 23

Annual Report 2020

The Annual Report has been presented and adopted at the Annual General Meeting on 12 May 2021.



Chairman of the meeting

Contents

	Page
Management statement and Auditor's report	
Statement by the Board of Directors and Executive Management	3
Independent Auditor's report	4
Management Report	
Company information	6
Management Review	7
Financial Statements 1 January – 31 December 2020	
Income statement	8
Balance sheet	9
Statement of changes in equity	10
Accounting policies	11
Notes	12

Statement by the Board of Directors and Executive Management

Today, the Board of Directors and Executive Management have approved the Annual Report of Novo Nordisk Invest 4 A/S for the year 2020.

The Annual Report has been prepared in accordance with the Danish Financial Statements Act.

In our opinion, the Financial Statements give a true and fair view of the financial position of the company at 31 December 2020 and of the results of the company's operations for 2020 in accordance with the Danish Financial Statements Act.

We recommend that the Annual Report be adopted at the Annual General Meeting.

Bagsværd, 12 May 2021

Executive Management:



Peter Bøggild

Board of Directors:



Karsten Munk Knudsen
Chairman



Linette Nielsen



Thomas Haagen

Independent Auditor's report

To the Shareholder of Novo Nordisk Invest 4 A/S

Opinion

In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2020, and of the results of the Company's operations for the financial year 1 January - 31 December 2020 in accordance with the Danish Financial Statements Act.

We have audited the Financial Statements of Novo Nordisk Invest 4 A/S for the financial year 1 January - 31 December 2020, which comprise income statement, balance sheet, statement of changes in equity, summary of significant accounting policies and notes ("financial statements").

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Statement on Management's Review

Management is responsible for Management's Review.

Our opinion on the Financial Statements does not cover Management's Review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Financial Statements, our responsibility is to read Management's Review and, in doing so, consider whether Management's Review is materially inconsistent with the Financial Statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether Management's Review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, in our view, Management's Review is in accordance with the Financial Statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement in Management's Review.

Management's Responsibilities for the Financial Statements

Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of Financial Statements that are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the Financial Statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Independent Auditor's report

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the Financial Statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the Financial Statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Hellerup, 12 May 2021

PricewaterhouseCoopers

Statsautoriseret Revisionspartnerselskab

CVR No 33 77 12 31



Mads Melgaard

State Authorised Public Accountant

mne34354

Company information

Company

Novo Nordisk Invest 4 A/S
c/o Novo Nordisk A/S
Novo Allé
2880 Bagsværd
Denmark

CVR no.: 31 85 39 23
Founded: 17 November 2008
Municipality of domicile: Gladsaxe
Financial year: 1 January – 31 December

Board of Directors

Karsten Munk Knudsen, chairman
Linette Nielsen
Tomas Haagen

Executive Management

Peter Bøggild

Auditors

PricewaterhouseCoopers
Statsautoriseret Revisionspartnerselskab
Strandvejen 44
2900 Hellerup
Denmark

General meeting

The Annual General Meeting will be held on 12 May 2021 at the company's address.

Management Review

Main activities

The company's main activities are the holding of equity investments in companies, and other investments, as well as financial activities, and - at the discretion of the Board of Directors - supporting the operations of such companies.

Principal activities

As of 1 January 2017 the company transferred its main activities to the Capital Region of Denmark. The transfer included the operation of a hospital and research and educational activities primarily within the field of diabetes treatment. After the transfer the company continues as a dormant company.

Development during the financial year

Net loss for Novo Nordisk Invest 4 A/S ended at DKK 108 thousand for the year 2020 compared with a net loss of DKK 398 thousand for the year 2019.

Events after the balance sheet date

No events have occurred after the end of the reporting period that materially affect the financial position of the company.

Income statement

	Note	2020 DKK '000	2019 DKK '000
Administrative costs		72	62
Operating income/(loss)		(72)	(62)
Financial income	1	2	-
Financial expenses	2	53	-
Profit/(loss) before income taxes		(123)	(62)
Income taxes		(15)	255
Profit/(loss) from ongoing operation		(108)	(317)
Profit/(loss) from discontinued operation	3	-	(81)
NET PROFIT/(LOSS) FOR THE YEAR	4	(108)	(398)

For proposed appropriation of net profit see note 4.

Balance sheet at 31 December

	2020	2019
Note	DKK '000	DKK '000
ASSETS		
Amounts owed by affiliated companies	2,235	9,160
Tax receivables	41	-
TOTAL CURRENT ASSETS	2,276	9,160
TOTAL ASSETS	2,276	9,160
EQUITY AND LIABILITIES		
Share capital	6	1,000
Retained earnings	816	924
Proposed dividends	-	7,000
TOTAL EQUITY	1,816	8,924
Amounts owed to affiliated companies	410	-
Tax payables	12	193
Other liabilities	38	43
TOTAL CURRENT LIABILITIES	460	236
TOTAL LIABILITIES	460	236
TOTAL EQUITY AND LIABILITIES	2,276	9,160

Statement of changes in equity at 31 December

	Share capital DKK '000	Retained earnings DKK '000	Proposed dividends DKK '000	Total DKK '000
2020				
Balance at the beginning of the year	1,000	924	7,000	8,924
Net profit/(loss) for the year		(108)		(108)
Dividends paid			(7,000)	(7,000)
Balance at the end of the year	1,000	816	-	1,816
2019				
Balance at the beginning of the year	1,000	1,315	7,000	9,315
Net profit/(loss) for the year		(398)		(398)
Exchange rate adjustments of investments in subsidiaries		7		7
Balance at the end of the year	1,000	924	7,000	8,924

Accounting policies

Accounting basis

The Annual Report of the company is prepared in accordance with the Danish Financial Statements Act for a class B enterprise as well as selected rules applying to reporting class C.

In accordance with the Danish Financial Statements Act § 86 a separate statement of cash flow has not been prepared. Reference is made to the statement of cash flow presented for the parent company.

As of 1 January 2017 the activity in the company was transferred to the Capital Region of Denmark. The discontinuation of the activities are shown separately both in the income statement and the balance sheet. Discontinued operations are presented in accordance with DFSA §§ 55 and 80.

The Annual Report is presented in DKK 1,000.

Income Statement

Administrative costs

Administrative costs comprise of audit fee and administrative costs.

Financial items

Financial income and expenses include interests income and expenses, realised and unrealised gains and losses on transactions denominated in foreign currencies. Financial income and expenses are recognised at the amounts that concern the reporting period.

Balance Sheet

Financial assets

Investments in subsidiaries are recorded under the equity method, using the respective share of the net asset values in subsidiaries. The equity method is used as a measurement basis rather than a consolidation method.

Net revaluation of equity investments in subsidiaries exceeding the declared dividend of the subsidiaries is transferred to equity as net revaluation reserve according to the equity method.

Amounts owed by affiliated companies

Amounts owned by affiliated companies mainly consists of payments made to the cash pool for the Novo Nordisk group and other receivables from affiliated companies.

Tax

Tax payable/receivable includes tax payable computed on the basis of the expected taxable income for the year and any adjustments of taxes payable for previous years.

Income tax in the income statement comprises current tax for the year and any change in the provision for deferred tax.

The company is jointly taxed with the Danish companies in the Novo Holdings A/S Group. The tax effect of the joint taxation with the parent company and other subsidiaries is allocated to the companies in proportion to their taxable incomes (full allocation). The current tax in the joint taxation is paid by the ultimate parent company, Novo A/S, which functions as the tax administration company. The jointly taxed Danish enterprises have adopted the on-account taxation scheme.

Dividends

Proposed dividends (not yet declared) for the accounting period are recognised in the equity as proposed dividends.

Discontinued operations

Discontinued operations comprise those activities that were disposed of 1 January 2017, and represent a separate major line of business that can be clearly distinguished for operational and financial reporting purposes.

Notes

1 - Financial income	2020	2019
	DKK '000	DKK '000
Foreign exchange rate gain (net)	2	-
Total financial income	2	-

2 - Financial expenses	2020	2019
	DKK '000	DKK '000
Other financial expenses	53	-
Total financial expenses	53	-

3 - Profit/(loss) from discontinued operation	2020	2019
	DKK '000	DKK '000
Administrative expenses	-	10
Operating profit/(loss)	-	(10)
Profit/(loss) in subsidiary	6	(73)
Profit before income taxes	-	(83)
Income taxes	-	(2)
Net profit/(loss) from discontinued operation	-	(81)

4 - Proposed appropriation of net profit	2020	2019
	DKK '000	DKK '000
Retained earnings	(108)	(398)
Distribution of net profit	(108)	(398)

5 - Share capital

The share capital consists of 10,000 shares of nominal DKK 100. No shares carry any special rights.

6 - Financial assets	2020	2019
	DKK '000	DKK '000
Cost at the beginning of the year	-	920
Divestments during the year	-	(920)
Cost at the beginning of the year	-	-
Value adjustments at the beginning of the year	-	(696)
Profit/(loss) before tax	-	(73)
Divestments during the year	-	762
Effect of exchange rate adjustment	-	7
Value adjustments at the end of the year	-	-
Carrying amount at the end of the year	-	-

Financial asset consisted of a subsidiary in Malaysia. The subsidiary has been liquidated in 2019.

Notes

7 - Contingencies

Novo Nordisk A/S and its Danish subsidiaries are jointly taxed with the Danish companies in the Novo Holdings A/S Group. The joint taxation also covers withholding taxes in the form of dividend tax, royalty tax and interest tax. The Danish companies are jointly and individually liable for the joint taxation. Any subsequent adjustments to income taxes and withholding taxes may lead to a larger liability. The tax for the individual companies is allocated in full on the basis of the expected taxable income.

The company has no other contingent liabilities.

8 - Related party transactions

All transactions with related parties have been carried out at arm's length principle.

9 - Ownership

Controlling interests

Novo Nordisk A/S, Novo Allé, 2880 Bagsværd, Danmark
Novo Holdings A/S, Tuborg Havnevej 19, 2900 Hellerup, Denmark
Novo Nordisk Foundation, Tuborg Havnevej 19, 2900 Hellerup, Denmark

Basis

Principal shareholder, owns 100%
Controls Novo Nordisk A/S
Ultimate parent of the Group

The company is included in the consolidated financial statements of Novo Nordisk A/S.